B+
Bull case
25%
Probability
Target price
$5.10
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
EMBC
EmbectaBNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+1Most likely
B
Base case
50%
Probability
Target price
$4.84
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$4.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-08
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+53.3
Score
AI commentary
Primary-source earnings evidence is directionally positive sequentially but mixed year over year. Analyst estimate or target revisions and verified post-print price reaction are unavailable; social coverage is also unavailable. The low-coverage, early post-earnings setup supports monitoring rather than a high-conviction directional thesis.
RankAlpha Sentiment Codex - 2026-08-08
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-07eventQ3 FY2026 sequential recovery and guidance improvementMedium impact
Q3 revenue rose approximately $50 million sequentially, while GAAP operating income rose approximately $14 million and adjusted operating income approximately $21 million. Management reaffirmed fiscal-year revenue guidance and raised adjusted operating-margin and adjusted-EPS guidance. However, reported revenue fell 8.1% year over year and U.S. revenue fell 24.6%. [#SEC-8K-2026-08-07]
2026-09-30catalystEvidence of U.S. demand stabilizationMedium impact
A sustained recovery in U.S. volumes and execution would be the key near-term confirmation of the Q3 improvement; the prior quarter cited competitive pressure and softer market volumes as major issues. [#SEC-8K-2026-05-05]
2027-03-31catalystOwen Mumford integration and portfolio diversificationHigh impact
The Owen Mumford acquisition contributed during Q3 and is intended to broaden embecta beyond insulin-injection delivery and strengthen its B2B drug-delivery platform. Integration benefits remain prospective. [#SEC-8K-2026-08-07]
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-08 • Updated nightlySource: Internal modelMethodology